Abstract
Gastrointestinal carcinomas have the highest incidence and mortality worldwide. In this collection consisting of 26 original research articles, two reviews and a clinical case report, we focus on endoscopic characterization of gastrointestinal neoplasias (GN) and the emerging role of circulating biomarkers, commonly known as liquid biopsies. In addition, we present articles on histopathological markers, which may be useful for decision making after endoscopic resection.
Introduction
Gastrointestinal (GI) carcinomas represent a significant portion of the global cancer burden, accounting for the highest incidence and mortality rates of any cancer group worldwide. The "holy grail" of oncology remains the early detection and precise characterization of these malignancies, as early-stage cancer is often asymptomatic and difficult to distinguish from benign inflammation or healthy tissue. This editorial synthesizes a collaborative effort across 29 papers to transition GI cancer screening from invasive, subjective endoscopic assessments toward a multi-modal, high-precision approach.
Innovations in Endoscopic and Radiomic Characterization
Current diagnostic standards, such as chromoendoscopy using Lugol’s solution, are limited by low specificity, frequently resulting in false positives and unnecessary clinical interventions. To address this, researchers are exploring advanced imaging techniques:
- Enhanced Visualization: Techniques such as 5-aminolevulinic acid (5-ALA)-mediated photodynamic diagnosis and magnifying endoscopy are being utilized to identify lesions that remain invisible under standard white-light imaging.
- Radiomics and AI Integration: Machine learning is being applied to extract quantitative features from dual-energy CT scans and Diffusion-Weighted Imaging (DWI). A radiomics model developed for gastric cancer achieved an Area Under the Curve (AUC) of 0.93 for predicting serosal invasion, significantly outperforming traditional CT imaging, which typically ranges from 0.55 to 0.90 in accuracy.
- Synergistic Clinical Approaches: For esophageal lesions, evidence suggests that combining endoscopic resection with radiofrequency ablation of surrounding "voiding lesions" (areas that do not take up iodine stain) can significantly reduce recurrence rates.
The Emerging Role of Liquid Biopsies and Molecular Biomarkers
Liquid biopsies offer a transformative, non-invasive method for cancer detection by analyzing circulating genetic and metabolic material.
- Tumor-Educated Platelets (TEPs): One of the most significant insights in this collection is the ability of tumors to alter the behavior and RNA profile of platelets. A simple 3-gene RNA signature derived from these "educated" platelets was able to distinguish esophageal cancer patients from healthy controls with 87.5% sensitivity and 81.1% specificity.
- DNA Methylation Patterns: New multi-target stool DNA methylation tests, targeting markers such as SDC2, TFPI2, WIF1, and NDRG4, show promise as screening tools for both gastric and colorectal cancers. Additionally, a six-CpG-marker nomogram has been validated to predict Hepatocellular Carcinoma (HCC) from blood samples.
- Metabolic Fingerprinting: Esophageal cancer development is accompanied by persistent changes in oxidative stress. While these metabolic fingerprints can identify the presence of cancer—including Stage-I pancreatic cancer—they are currently more effective at detection than at distinguishing between early and late stages.
Histopathological and Prognostic Indicators
Precise characterization extends to the cellular level, where histopathological markers guide post-resection decision-making. Identifying specific protein markers, such as GPX8 or MAGE-A3, in tissue samples allows clinicians to predict immunotherapy response and overall patient prognosis. Furthermore, chemokine expression analysis in colorectal cancer cohorts (e.g., 160 patients) provides a more nuanced understanding of tumor staging and potential for metastasis.
Challenges and Future Directions
Despite the promising results of these multi-modal approaches, several hurdles remain before they can be integrated into routine clinical practice:
- Confounding Variables: Biomarker studies, particularly those involving platelet RNA, must account for the effects of smoking, geography, and ethnicity, which can influence results.
- Sample Size and Validation: Many studies, such as those testing 5-ALA diagnostic yields, relied on small pilot cohorts (e.g., n=43). There is a critical "validation gap" that requires these models and nomograms to be tested in larger, diverse, multi-center real-world populations.
- Marker Specificity: The clinical utility of older markers, such as Chromogranin A (CgA) for neuroendocrine tumors, remains controversial due to elevation in non-cancerous conditions, highlighting the need for the high-specificity markers discussed in this collection.
In conclusion, the integration of radiomics, liquid biopsies, and metabolic profiling represents a significant step toward the early and accurate detection of gastrointestinal cancers, potentially reducing mortality through earlier intervention and more personalized treatment strategies.
Summary updated